EP1003713A1 - Analogues d'acide anthranilique - Google Patents

Analogues d'acide anthranilique

Info

Publication number
EP1003713A1
EP1003713A1 EP98938221A EP98938221A EP1003713A1 EP 1003713 A1 EP1003713 A1 EP 1003713A1 EP 98938221 A EP98938221 A EP 98938221A EP 98938221 A EP98938221 A EP 98938221A EP 1003713 A1 EP1003713 A1 EP 1003713A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
amino
compound
aryl
alkylcarboxamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938221A
Other languages
German (de)
English (en)
Inventor
Joseph Richard Lennox
Schuyler Adam Antane
John Anthony Butera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1003713A1 publication Critical patent/EP1003713A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Definitions

  • the present invention relates to a novel series of anthranilic acid-derived amides (I) having pharmacological activity, to a process for their preparation, to pharmaceutical compositions containing them, and to their use in the treatment of disorders associated with smooth muscle contraction, via potassium channel and chloride channel modulation.
  • disorders include, but are not limited to: urinary incontinence, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina, and cerebral vascular disease.
  • Patent No. J6 0097-946-A discloses a series of substituted carboxamide derivatives which exhibit activity as leucotriene antagonists and phospholipase inhibitors.
  • R , R and R are, independently, hydrogen, nitro, cyano, C. .10 haloalkoxy, amino, C, .10 alkylamino, sulfo, sulfamoyl, C. .10 alkylsulfonamido, C 2.10 alkylcarboxamido C 2.10 alkanoyl, C. .10 alkylsulfonyl, C, .10 haloalkylsulfonyl, C, .10 carboxyl, C. .10 haloalkyl and C g. ,- aryl; with the provisos: (1) that R,, R 2 and R 3 may not all simultaneously be hydrogen, and (2) when R, and R 2 are hydrogen, R 3 may not be meta-CF 3 ;
  • R 4 , R 5 and R fi are, independently, hydrogen, halogen, nitro, cyano, C 0 carboalkoxy, C, . , 0 haloalkoxy, amino C, .10 alkylamino, sulfo, sulfamoyl, C, .10 alkylsulfonamido, C 2.10 alkylcarboxamido C 2.10 alkanoyl, C. .10 alkylsulfonyl, C, .I0 haloalkylsulfonyl, C ⁇ 0 carboxyl, C, .10 haloalkyl, C. .I0 alkyl and C 6.12 aryl;
  • R 7 is hydrogen, metal cation, acetylamido, alkoxyacetoyl or a related moiety which delivers the carboxylate in vivo;
  • X, Y and Z may form a C 3.13 carbocyclic ring, oxazole, isoxazole, thiazole, isothiazole, furan, thiophene, 2H-pyrrole, pyrrole, 2- pyrroline, 3-pyrroline, imidazole, pyrazole, 1,2,3-oxadiazole or 1,2,3- triazole bound to the carbon skeleton.
  • R, , R 2 and R 3 are, independently, hydrogen, nitro, cyano, perhaloalkoxy, amino, C. .10 alkylamino, C, .10 dialkylamino, C arylamino, C, .10 aralkylamino, sulfo, sulfamyl, C,. 10 alkylsulfonamido, C 6.12 arylsulfonamido, C 2.I0 alkylcarboxamido, C 6. , 2 arylcarboxamido,
  • R 4 , R 5 , and R 6 are, independent of each other, hydrogen, halogen, nitro, cyano, carboalkoxy, perhaloalkoxy, amino, C,_ 10 alkylamino, C, .10 dialkylamino, arylamino, C. .10 aralkylamino, sulfo, sulfamyl, C, .
  • haloalkyl C. . , 0 perhaloalkyl, C 2.12 alkenyl (single or multiple olefinic), aryl, haloaryl, perhaloaryl, C, .10 aralkyl;
  • R 7 is a hydrogen, an alkali metal cation, an alkaline earth metal cation, acetylamido, alkoxyacetoyl, or related moieties which deliver the carboxylate in vivo;
  • X, Y and Z may form a C 3.13 carbocyclic ring, oxazole, isoxazole, thiazole, or isothiazole, bound to the carbon skeleton.
  • Still more preferred aspects of this invention includes compounds of formula (I) wherein:
  • R,, R 2 , R 3 , R 4 , R 5 , and R 6 are as hereinbefore defined;
  • R 7 is selected from the group consisting of hydrogen, a metal cation, a moiety selected from:
  • R 9 , R ]0 , R u and R 12 are, independent of each other, hydrogen, C 0 straight chain alkyl, C, .]0 branched alkyl, C 3.10 cyclic or bicyclic, aryl, or C. .10 aralkyl;
  • X, Y and Z may form a C 3.I3 carbocyclic ring, oxazole, isoxazole, thiazole, or isothiazole, bound to the carbon skeleton;
  • a most preferred aspect of this invention includes compounds of the formula (I) wherein R 7 may be hydrogen, or a metal cation as previously described.
  • the pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
  • R., R ⁇ , R 3 , R 4 , R 5 , R 6 , or the ring system formed by X, Y and Z contains a carboxyl group
  • salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg).
  • the present invention also provides a process for the preparation of compounds of the formula (I). Methods of preparation are shown in Schemes 1 through 4.
  • Isoxazoles of the formula (1) may be prepared (Scheme 1) by nitrile oxide cycloaddition of a compound of the formula (II) with an appropriate nitrile oxide (III) to give heterocycle (IV). As above, saponification gives intermediate carboxylic acid (V)
  • Oxazoles of the formula (I) may be prepared (Scheme 2) via condensation of the appropriate benzoyl chloride (VI) with methyl isocyanoacetate (VII) to give the heterocycle (VIII). As above, saponification affords the intermediate carboxylic acid
  • R,, R 2 and R 3 are equivalent to the aforementioned R,, R 2 , and R
  • Carboxylic acid intermediates (V), (VI), or (XII) could subsequently be coupled (Scheme 4) to the amine of an appropriately derivatized anthranilic acid of the formula (XIII) utilizing one of the following established coupling procedures (Method A: (COCl) 2 , cat. DMF, CH 2 C1 2 , then add the neat acid chloride to a solution of anthranilic acid in sodium hydroxide; Method B: diisopropylcarbodiimide, DMAP, CH 2 C1 2 , then add methyl anthranilate; or Method C: (COCl) 2 , cat.
  • the reactions mentioned above may be carried out in aprotic solvents such as diethyl ether, dichloroethane, dioxane or THF at low to ambient temperatures.
  • aprotic solvents such as diethyl ether, dichloroethane, dioxane or THF at low to ambient temperatures.
  • sodium hydroxide is used as a base
  • other inorganic bases which may also suffice are lithium hydroxide or potassium hydroxide, etc.
  • triethylamine may be optionally substituted with any trialkylamine.
  • the compounds of formula (I), and their pharmaceutically acceptable salts have been found to relax smooth muscle. They are therefore useful in the treatment of disorders associated with smooth muscle contraction, disorders involving excessive smooth muscle contraction of the urinary tract (such as incontinence), or of the gastro-intestinal tract (such as irritable bowel syndrome), asthma, and hair loss.
  • the compounds of formula (I) are active as potassium channel activators which render them useful for treatment of peripheral vascular disease, congestive heart failure, stroke, anxiety, cerebral anoxia and other neurodegenerative disorders.
  • compounds of formula(s) (I) and (II) may also be active as chloride channel blockers, which again renders them useful for treatment of the above stated disorders.
  • Compounds of the present invention are characterized by their potent smooth muscle relaxing properties in vitro.
  • the compounds of this invention exert their smooth muscle relaxatory activity via activation of potassium channels and/or blocking of chloride channels (Table 1).
  • Comparative compound, Tranilast ® was shown not to be a potent or bladder selective smooth muscle relaxant.
  • the present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier.
  • the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.
  • compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example, parenteral administration for patients suffering from heart failure.
  • a composition of the invention is in the form of a unit dose.
  • Suitable unit dose forms include tablets, capsules and powders in sachets or vials.
  • Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg.
  • Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention.
  • the compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg.
  • Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.
  • compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics and ⁇ - blocking agents.
  • the present invention further provides a compound of the invention for use as an active therapeutic substance.
  • Compounds of formula (I) are of particular use in the induction of smooth muscle relaxation.
  • the present invention further provides a method of treating smooth muscle disorders in mammals including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.
  • the neat acid chloride was then added to a homogeneous solution of anthranilic acid (535 mg, 3.90 mmol) in 2.5 N aqueous NaOH (3.12 mL, 7.80 mmol) at 5°C, resulting in the instantaneous formation of a white precipitate.
  • the reaction mixture was then warmed to RT, whereupon it was diluted with a minimal amount of water to facilitate stirring, which was continued for an additional 1.5 h.
  • the mixture was acidified to pH 2 by addition of concentrated HC1 (0.75 mL), diluted with 2.0 N HC1, and stirred for 1.5 h.
  • Step 1) Preparation of 5-(4-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid methyl ester
  • 4-trifluoromethylbenzoyl chloride 8.42 g, 40.4 mmol
  • triethylamine 12.3 g, 122 mmol
  • methyl isocyanoacetate 3.60 g, 36.3 mmol
  • the resultant mixture was stirred at RT for 72 h whereupon all volatiles were removed via rotary evaporation, giving a residue which was partitioned between EtOAc (300 mL) and water (100 mL).
  • the dibromoolefin was dissolved in anhydrous THF (115 mL) and chilled to -78°C. To this solution was added dropwise via syringe pump over 1 h 2.5 M butyllithium (18.4 mL, 46.0 mmol). The resultant mixture was then stirred fo 0.5 h at -78°C, then treated with methyl chloroformate (5.00 mL, 64.7 mmol), followed by slow warming to RT, whereupon it was concentrated to an oily residue which was partitioned between ether (500 mL) and water (250 mL).
  • the acid chloride was then added to a homogeneous solution of anthranilic acid (1.19 g, 8.69 mmol) in 2.5 N aqueous NaOH (6.95 mL, 17.4 mmol) at 5°C, resulting in the instantaneous formation of a white precipitate.
  • the reaction mixture was then warmed to RT, whereupon it was diluted with a minimal amount of water to facilitate stirring, which was continued for an additional 1.5 h.
  • the mixture was acidified to pH 2 by addition of concentrated HCl (1.63 mL), diluted with 2.0 N HCl, and stirred for 1.5 h. Filtration of the suspension followed by washing with water, air drying and subsequent recrystallization from MeOH.
  • Sprague-Dawley rats (150-200 g) are rendered unconscious by CO 2 asphyxiation and then euthanized by cervical dislocation.
  • the bladder is removed into warm (37 deg.C) physiological salt solution (PSS) of the following composition (mM): NaCl, 118.4; KC1, 4.7; CaCl 2 , 2.5; MgSO 4 , 4.7; H 2 O, 1.2; NaHCO 3 , 24.9; KH 2 PO 4 , 1.2; glucose, 11.1; EDTA, 0.023; gassed with 95% O 2 ; 2/5% CO 2 ; pH 7.4.
  • the bladder is opened and then cut into strips 1-2 mm in width and 7-10 mm in length.
  • the strips are subsequently suspended in a 10 mL tissue bath under an initial resting tension of 1.5 g.
  • the strips are held in place by two surgical clips one of which is attached to a fixed hook while the other is attached to an isometric force transducer.
  • the preparations which usually exhibit small spontaneous contractions, are allowed to recover for a period of 1 hour prior to a challenge with 0.1 ⁇ M carbachol.
  • the carbachol is then washed out and the tissue allowed to relax to its resting level of activity. Following a further 30 min period of recovery an additional 15 mM KC1 are introduced into the tissue bath.
  • Tranilast ® ⁇ 2 14.4 ⁇ 4.5 5 15.59 ⁇ 8.96 1.08
  • Tranilast is (E)-2-[3-(3,4-Dimethoxy-phenyl)-acryloylamino]-benzoic acid. *Percent inhibition at 30 ⁇ M
  • mice Female Sprague-Dawley rats, ranging in weight from 190-210g are used. Up to 25 animals are prepared each time. After development of bladder hypertrophy 4-8 animals are used per test. Compounds are dissolved in PEG-200 and administered by gastric gavage or intraveneously in a volume of 5 mL/kg. For primary screening all drugs are administered at the arbitrary dose of 10 mg/kg p.o. to groups of 4 rats.
  • the animals are anesthetized with halothane.
  • halothane Through a midline incision the bladder and urethra are exposed and a ligature of 4-0 silk is tied around the proximal urethra in the presence of a stainless steel rod (1 mm diameter) to produce a partial occlusion. The rod is then removed. The abdominal region is closed using surgical staples and each rat receives 150,000 units of bicillin C-R. The animals are allowed six weeks to develop sufficient bladder hypertrophy. After six weeks, the ligature is removed under halothane anesthesia and a catheter (PE 60) with a cuff is placed in the dome of the bladder and secured with a purse string suture.
  • PE 60 catheter
  • the catheter is tunneled under the skin and exteriorized through an opening in the back of the neck.
  • the abdominal incision is sutured and the free end of the catheter sealed.
  • the rats receive an injection of bicillin C-R (150000 units/rat).
  • Two days later the animals are used in cystometrical evaluations.
  • the animals are placed in the metabolic cages and the catheter is attached (using a "T" connector) to a Statham pressure transducer (Model P23Db) and to a Harvard infusion pump.
  • a plastic beaker attached to a force displacement transducer (Grass FTO3) is placed under the rat's cage to collect and record urine volume.
  • Basal bladder pressure the lowest bladder pressure during cystometry
  • Threshold pressure bladder pressure immediately prior to micturition
  • Micturition volume volume expelled
  • the mean value of each variable is calculated before and after compound administration. For each compound the changes in the variables measured are compared to the values obtained before treatment and expressed as percent inhibition.
  • the data are also subjected to 2-way analysis of variance to determine significant (p ⁇ 0.05) changes in the variable measured.
  • Criteria for Activity The most characteristic finding in this rat model is spontaneous bladder contractions which develop during filling.
  • the compounds which inhibit spontaneous contractions by at least 50% at 10 mg/kg p.o. or i.v. (arbitrary chosen dose) are considered active.
  • the compounds of this invention have a pronounced effect on smooth muscle contractility and are useful in the treatment of urinary incontinence, irritable bladder and bowel disease, asthma, hypertension, stroke, and similar diseases as mentioned above, which are amenable to treatment with potassium channel activating and/or chloride channel blocking compounds by administration, orally, parenterally, or by aspiration to a patient in need thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composés de formule (I), dans laquelle R1, R2 et R3 représentent indépendamment, hydrogène, nitro, cyano, haloalcoxy C1-10, amino, alkylamino C1-10, sulfo, sulfamoyle, alkylsulfonamido C1-10, alkylcarboxamido C2-10 alcanoyle C2-10, alkylsulfonyle C1-10, haloalkylsulfonyle C1-10, carboxyle C1-10, haloalkyle C1-10 et aryle C6-12; à condition: (1) que R1, R2 et R3 ne peuvent pas être simultanément hydrogène, et (2) lorsque R1 et R2 représentent hydrogène, R3 ne peut pas être méta-CF3; R4, R5 et R6 représentent séparément hydrogène, halogène, nitro, cyano, carboalcoxy C1-10, haloalcoxy C1-10, amino C1-10 alkylamino, sulfo, sulfamoyle, alkylsulfonamido C1-10, alkylcarboxamido C2-10 alcanoyle, alkylsulfonyle C1-10, haloalkylsulfonyle C1-10, carboxyle C1-10, haloalkyle C1-10, alkyle C1-10 et aryle C6-12; R7 représente hydrogène, cation métal, acétylamido, alcoxyacétoyle, ou une partie associée qui dégage le carboxylate in vivo; et X, Y et Z peuvent former un cycle carboxylique, oxazole, isoxazole, thiazole, isothiazole, furane, thiophène, 2H-pyrrole, pyrrole, 2-pyrroline, 3-pyrroline, imidazole, pyrazole, 1,2,3-oxadiazole ou 1,2,3-triazole lié au squelette carboné; ou des sels pharmaceutiquement acceptables de ceux-ci, utiles dans le traitement de troubles associés à une contraction d'un muscle lisse, par modulation du canal potassium et le canal chlorure.
EP98938221A 1997-08-05 1998-08-03 Analogues d'acide anthranilique Withdrawn EP1003713A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US905930 1992-06-26
US90593097A 1997-08-05 1997-08-05
PCT/US1998/015981 WO1999007670A1 (fr) 1997-08-05 1998-08-03 Analogues d'acide anthranilique

Publications (1)

Publication Number Publication Date
EP1003713A1 true EP1003713A1 (fr) 2000-05-31

Family

ID=25421704

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938221A Withdrawn EP1003713A1 (fr) 1997-08-05 1998-08-03 Analogues d'acide anthranilique

Country Status (7)

Country Link
EP (1) EP1003713A1 (fr)
JP (1) JP2001513527A (fr)
CN (1) CN1265643A (fr)
AU (1) AU734786B2 (fr)
BR (1) BR9811828A (fr)
CA (1) CA2297409A1 (fr)
WO (1) WO1999007670A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1565190A4 (fr) * 2002-11-22 2006-04-26 Bristol Myers Squibb Co Amides arylcyclopropylcarboxyliques utilises en tant qu'agents d'ouverture des canaux potassiques
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB2434794A (en) * 2006-02-03 2007-08-08 Prom Ltd Continuous process for forming anthranilic acid and treatment of waste water containing organic material
WO2008011453A2 (fr) 2006-07-20 2008-01-24 Amgen Inc. HÉTÉROCYCLES AROMATIQUES D'AZOLE SUBSTITUÉS, UTILISÉS EN TANT QU'INHIBITEURS DE LLβ-HSD-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5970654A (ja) * 1982-10-15 1984-04-21 Nippon Redarii Kk アントラニル酸誘導体
JPS6097946A (ja) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd カルボキサミド誘導体
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9907670A1 *

Also Published As

Publication number Publication date
AU734786B2 (en) 2001-06-21
AU8679598A (en) 1999-03-01
WO1999007670A1 (fr) 1999-02-18
CA2297409A1 (fr) 1999-02-18
JP2001513527A (ja) 2001-09-04
CN1265643A (zh) 2000-09-06
BR9811828A (pt) 2000-08-15

Similar Documents

Publication Publication Date Title
US6096770A (en) Anthranilic acid analogs
KR100522011B1 (ko) 설폰아미드 및 카르복사미드 유도체와, 이들을 유효 성분으로 함유하는 약제
US6046239A (en) Anthranilic acid analogs
AU2003261826A1 (en) Dibenzylamine compound and medicinal use thereof
JPWO2006059744A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
US6127392A (en) Anthranilic acid analogs
JP2000515133A (ja) 血糖降下性および脂質低下性の化合物
JPH0572394B2 (fr)
US5464849A (en) N-hydroxyurea derivatives as antiallergy and antiinflammatory agents
AU734786B2 (en) Anthranilic acid analogs
JPH0649047A (ja) フェニルカルボキサミドイソオキサゾールの新誘導体及びそれらの塩類、それらの製造法及びこの製造法の新規な中間体、それらの薬剤としての用途並びにそれらを含有する製薬組成物
EP1003712A1 (fr) Analogues d'acide anthranilique
JPH0625178B2 (ja) アミノケトン誘導体及びその用途
MXPA00001255A (en) Anthranilic acid analogs
EP0934257B1 (fr) Derives a substitution n-arylmethylamino de cyclobutene-3,4-diones
AU727217B2 (en) Heterocyclylmethylamino derivatives of cyclobutene-3,4- diones as potassium channel modulators
JP3454531B2 (ja) ニトロキシアルキルアミド誘導体
RU2178786C2 (ru) Производные 4-(1-пиперазинил)бензойной кислоты, способ их получения и фармацевтическая композиция
JP3134097B2 (ja) オキサゾール化合物
CN113651767B (zh) 一种苯并异噁唑类杂环化合物及其制备方法和应用
US5872139A (en) Heterocyclymethylamino derivatives of cyclobutene-3,4-diones
AU2163500A (en) 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction
KR960008245B1 (ko) 로다닌 유도체 및 약제학적 조성물
US5194442A (en) 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds
RU2198881C2 (ru) α-(1-ПИПЕРАЗИНИЛ)АЦЕТАМИДОПРОИЗВОДНЫЕ АРЕНКАРБОНОВОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБЫ ЛЕЧЕНИЯ

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000118;LT PAYMENT 20000118;LV PAYMENT 20000118;MK PAYMENT 20000118;RO PAYMENT 20000118;SI PAYMENT 20000118

17Q First examination report despatched

Effective date: 20020422

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027800

Country of ref document: HK